===Side effects===

 
At the maximum tolerated dose (MTD) of 960&nbsp;mg twice a day 31% of patients get skin lesions that may need surgical removal.<ref name="pmid20823850"/> The BRIM-2 trial investigated 132 patients; the most common adverse events were [[arthralgia]] in 58% of patients, skin rash in 52%, and photosensitivity in 52%. In order to better manage side effects some form of dose modification was necessary in 45% of patients. The median daily dose was 1750&nbsp;mg, 91% of the MTD.<ref>{{cite journal | title=BRIM-2 Upholds Benefits Emerging with Vemurafenib in Melanoma |journal=Oncology & Biotech News |volume=5 |issue=7 |date=July 2011 |url=http://www.onclive.com/publications/obtn/2011/july-2011/BRIM-2-Upholds-Benefits-Emerging-with-Vemurafenib-in-Melanoma }}</ref>
